CRISPR Therapeutics is a gene editing specialist. It developed Casgevy, a medicine for two rare blood diseases, in collaboration with Vertex Pharmaceuticals. Casgevy doesn't generate much revenue yet, ...

These two drugmakers are highly innovative. They have important catalysts on the horizon. 10 stocks we like better than CRISPR Therapeutics › The biotech industry is on fire right now. Over the past ...

Be Biopharma’s terminated trial is the latest setback in the hemophilia space, where companies like Pfizer and BioMarin have opted to pull their respective products from the market after weak traction ...

Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track ...

Soligenix has scrapped its cutaneous T-cell lymphoma (CTCL) program in the wake of a phase 3 setback, leaving the biotech focused on another rare disease prospect and considering strategic ...

The staffing changes will focus resources on work that creates the highest impact for patients, according to Genentech. The number of employees affected is unknown, but longtime veteran Vishva Dixit ...

In this article, we will take a look at some of the best AI driven biotech stocks that are currently offering attractive upside potential. On June 4, CNBC reported that global biopharma mergers and ...

In this article, we will list the 5 Best AI Driven Biotech Stocks to Invest In. Please visit 10 Best AI Driven Biotech Stocks to Invest In if you’d like to see an extended list and how we came up with ...

WASHINGTON — The CIA officer found with $40 million in gold bars stashed at his home is accused of creating a fake top secret intelligence program to receive government funds for his personal ...